Takeshi Inoue

Takeshi Inoue

Auto-generated profile, based on publicly available information

Takeshi Inoue

Laboratory of Lymphocyte Differentiation, WPI Immunology Frontier Research Center, The University of Osaka, Osaka, Japan.

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2023 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
TITakeshi Inoue
Takeshi Inoue
TKTomohiro Kurosaki
Tomohiro Kurosaki

17 April 2018 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
TITakeshi Inoue
Takeshi Inoue
IMImogen Moran
Imogen Moran
RSRyo Shinnakasu
Ryo Shinnakasu
TPTri Giang Phan
Tri Giang Phan
TKTomohiro Kurosaki
Tomohiro Kurosaki

12 October 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
TITakeshi Inoue
Takeshi Inoue
RSRyo Shinnakasu
Ryo Shinnakasu
CKChie Kawai
Chie Kawai
WIWataru Ise
Wataru Ise
EKEiryo Kawakami
Eiryo Kawakami
TKTomohiro Kurosaki
Tomohiro Kurosaki
A still unanswered question is what drives the small fraction of activated germinal center (GC) B cells to become long-lived quiescent memory B cells. We found here that a small population of GC-derived CD38intBcl6hi/intEfnb1+ cells with lower mTORC1 activity favored the memory B cell fate. Constitutively high mTORC1 activity led to defects in formation of the CD38intBcl6hi/intEfnb1+ cells; conversely, decreasing mTORC1 activity resulted in relative enrichment of this memory-prone population over the recycling-prone one. Furthermore, the CD38intBcl6hi/intEfnb1+ cells had higher levels of Bcl2 and surface BCR that, in turn, contributed to their survival and development. We also found that downregulation of Bcl6 resulted in increased expression of both Bcl2 and BCR. Given the positive correlation between the strength of T cell help and mTORC1 activity, our data suggest a model in which weak help from T cells together with provision of an increased survival signal are key for GC B cells to adopt a memory B cell fate.

24 August 2021 in Immunity
Verified
Journal Article
Open access
TOTaishi Onodera
Taishi Onodera
SKShunsuke Kita
Shunsuke Kita
YAYu Adachi
Yu Adachi
SMSaya Moriyama
Saya Moriyama
ASAkihiko Sato
Akihiko Sato
YTYoshimasa Takahashi
Yoshimasa Takahashi
Potent neutralizing SARS-CoV-2 antibodies often target the spike protein receptor-binding site (RBS), but the variability of RBS epitopes hampers broad neutralization of multiple sarbecoviruses and drifted viruses. Here, using humanized mice, we identified an RBS antibody with a germline VH gene that potently neutralized SARS-related coronaviruses, including SARS-CoV and SARS-CoV-2 variants. X-ray crystallography revealed coordinated recognition by the heavy chain of non-RBS conserved sites and the light chain of RBS with a binding angle mimicking the angiotensin-converting enzyme 2 (ACE2) receptor. The minimum footprints in the hypervariable region of RBS contributed to the breadth of neutralization, which was enhanced by immunoglobulin G3 (IgG3) class switching. The coordinated binding resulted in broad neutralization of SARS-CoV and emerging SARS-CoV-2 variants of concern. Low-dose therapeutic antibody treatment in hamsters reduced the virus titers and morbidity during SARS-CoV-2 challenge. The structural basis for broad neutralizing activity may inform the design of a broad spectrum of therapeutics and vaccines.

13 December 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
TITakeshi Inoue
Takeshi Inoue
RSRyo Shinnakasu
Ryo Shinnakasu
CKChie Kawai
Chie Kawai
HYHiromi Yamamoto
Hiromi Yamamoto
SSShuhei Sakakibara
Shuhei Sakakibara
TKTomohiro Kurosaki
Tomohiro Kurosaki
In contrast to a second dose of the SARS-CoV-2 mRNA vaccine, a third dose elicits potent neutralizing activity against the Omicron variant. To address the underlying mechanism for this differential antibody response, we examined spike receptor-binding domain (RBD)–specific memory B cells in vaccinated individuals. Frequency of Omicron-reactive memory B cells increased ∼9 mo after the second vaccine dose. These memory B cells show an altered distribution of epitopes from pre-second memory B cells, presumably due to an antibody feedback mechanism. This hypothesis was tested using mouse models, showing that an addition or a depletion of RBD-induced serum antibodies results in a concomitant increase or decrease, respectively, of Omicron-reactive germinal center (GC) and memory B cells. Our data suggest that pre-generated antibodies modulate the selection of GC and subsequent memory B cells after the second vaccine dose, accumulating more Omicron-reactive memory B cells over time, which contributes to the generation of Omicron-neutralizing antibodies elicited by the third vaccine dose.

14 October 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
XLXiuyuan Lu
Xiuyuan Lu
YHYuki Hosono
Yuki Hosono
MNMasamichi Nagae
Masamichi Nagae
SIShigenari Ishizuka
Shigenari Ishizuka
EIEri Ishikawa
Eri Ishikawa
SYSho Yamasaki
Sho Yamasaki
Adaptive immunity is a fundamental component in controlling COVID-19. In this process, follicular helper T (Tfh) cells are a subset of CD4+ T cells that mediate the production of protective antibodies; however, the SARS-CoV-2 epitopes activating Tfh cells are not well characterized. Here, we identified and crystallized TCRs of public circulating Tfh (cTfh) clonotypes that are expanded in patients who have recovered from mild symptoms. These public clonotypes recognized the SARS-CoV-2 spike (S) epitopes conserved across emerging variants. The epitope of the most prevalent cTfh clonotype, S864–882, was presented by multiple HLAs and activated T cells in most healthy donors, suggesting that this S region is a universal T cell epitope useful for booster antigen. SARS-CoV-2–specific public cTfh clonotypes also cross-reacted with specific commensal bacteria. In this study, we identified conserved SARS-CoV-2 S epitopes that activate public cTfh clonotypes associated with mild symptoms.